Kornimate/medical-research-clean huggingface dataset:
coretox® in treatment of post stroke upper limb spasticity (phase1)

Conditions: Muscle Spasticity

Summary: the purpose of this study is to evaluate the safety and pharmacodynamic of coretox® in the treatment of post-stroke upper limb spasticity


Eligibility criteria:
inclusion criteria: * male or female patients ≥ 19 years * 6 months since the last stroke * 2 points in the focal spasticity of wrist flexor and ≥ 1 point at least one of elbow flexor and finger flexor as measured on mas(0 to 4) * informed consent has been obtained exclusion criteria: * neuromuscular disorders such as lambert-eaton syndrome, myasthenia gravis, or amyotrophic lateral sclerosis * history(within 4 months of screening visit) or planned(during study period) treatment with phenol or alcohol injection or surgery in the target limb * history(within 4 months of screening visit) or planned(during study period) treatment with tendon lengthening in the target limb * fixed joint/muscle contracture * severe atrophy * concurrent treatment with an intrathecal baclofen * patients who have bleeding tendency or taking anti-coagulant * dysphagia and breathing difficulties * history(within 4 months of screening visit) planned(during study period) treatment with botulinum toxin * known allergy or sensitivity to study medication or its components * concurrent or planed muscle relaxants and/or benzodiazepine medication if patient has taken these medication stable from one month before screening and no treatment changes are not planned during the study, participation is allowed. * current physical, occupational, splinting therapy these therapy regimens will be permitted if they have been stable in the one month before screening; no treatment and no changes are planned during the study. * patient who are participating in other clinical trials at the screening * females who are pregnant, breastfeeding, or planning a pregnancy during the study period, or female of childbearing potential, not using a reliable means of contraception. * patients who are not eligible for this study at the discretion of the investigator.
prognostic value of red density in ulcerative colitis

Conditions: Ulcerative Colitis

Summary: observational prospective multicenter study: baseline assessement of the disease activity by an automated endoscopic tool and follow up of 52 weeks to evaluate sustained clinical remission.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of uc for at least 3 months * clinical remission with sccai \<3 at baseline and stable remission for the last 3 months * ability to give informed consent by the patient or legal representative in case of minority. exclusion criteria: * any contraindication for sigmoidoscopy or undergoing biopsies of the rectosigmoid. * uncontrolled coagulopathy. * any planned change in uc related treatment (both escalation and de-escalation) after the baseline endoscopy * planned uc related surgery * previous subtotal or total colectomy * short bowel, ileostomy or colostomy * pregnancy at baseline * age younger than 16 years

Keywords: endoscopy artificial intelligence image analysis precision medicine inflammatory bowel disease
neuroinflammation and age-associated brain pathology: two potential mechanisms of cognitive impairment in ovarian cancer

Conditions: Ovarian Cancer

Summary: this clinical study will use the small molecule translocator protein (tspo) ligand, 18f-labeled dpa- 714, to visualize and quantify neuroinflammation in treatment naivete women with stage 1-4 newly diagnosed ovarian cancer (without brain metastases) prior to starting neoadjuvant chemotherapy treatment (baseline) and within a month of completing first 6 cycles of cytotoxic chemotherapy treatment (follow-up). in addition, we will use the well-characterized small molecule pet(positron emission tomography) tracer, 11c-labeled pittsburgh compound b (pib) to visualize and quantify the regional brain distribution of pathological amyloid deposition at baseline only. the brain amyloid pet and mri data acquired through this study will be correlated with cognitive test data, clinical data, genetic testing, and biospecimens collected in this study.


Eligibility criteria:
inclusion criteria: 1. 50 years of age or older 2. female gender 3. newly diagnosed treatment naïve women with stage iii/iv epithelial ovarian cancer (without known brain metastases). 4. high or mixed affinity binder for tspo ligands based on genotyping for single nucleotide polymorphism (snp) rs6971. 5. english is primary language 6. planned neoadjuvant chemotherapy with platinum and taxane drugs exclusion criteria: 1. contraindication to mri 2. pregnancy 3. lactation 4. individuals who are unable to participate in the imaging portion due to severity of their medical condition 5. chronic infectious disease (e.g. hiv, hcv) 6. chronic inflammatory disease (e.g., fibromyalgia, ms, etc) or autoimmune disease 7. viral or bacterial illness requiring medical attention and/or antibiotics within 1 month of study participation 8. blood or blood clotting disorder 9. cancer that has metastasized to the brain 10. positive urine hcg test day of procedure or a serum hcg test within 48 hours prior to the administration of \[18f\]dpa-714 and \[11c\]pib. 11. currently enrolled in a clinical trial utilizing experimental therapies. 12. low affinity binder for tspo ligands based on genotyping for snp rs6971. 13. prior brain tumor or other neurological condition known to affect cognition 14. a diagnosis of dementia unrelated to cancer or an adjusted mmse score \< 24
evaluating the use of a remote telehome monitoring hypertension program for patients receiving virtual care

Conditions: Hypertension

Summary: high blood pressure or hypertension (htn) is very common and can lead to serious health issues and even death. medications and lifestyle changes can be used to treat htn. during the coronavirus disease-19 (covid-19) pandemic, a lot of the care provided by doctors has become virtual, meaning that patients can be assessed by a doctor over the phone or video call without needing to go to a clinic or hospital. although this is convenient, a lot of people cannot get their blood pressure (bp) checked in a reliable way when they are at home. as a result, it is possible that their bps are too high and that they are not getting the right medications or the right doses of medications to treat this. the investigators are performing this study to see how patients are managing to check their bp's at home, during this time when a lot of the care is virtual. the investigative team understands that many patients diagnosed with htn don't have a home bp cuff, or might not know how to properly use it, or might not share the results with their doctors. in people who have high bp, we want to see if a special bp cuff and special monitoring program can help to get their bp's under better control, and to prevent negative effects related to htn.


Eligibility criteria:
inclusion criteria: * have a diagnosis of primary, essential htn (sbp\>140/90mmhg or \>130/80mmhg for diabetes) * have access to a phone (can be a landline) * have access to cellular (4g) network at their primary residence (they do not need to physically own a cellular phone but the need to be able to confirm their residence has 4g network access in order to connect the aetonix atouchaway platform to the network) * speak english or french exclusion criteria: * patients who have been referred or who are actively managed at a specialized htn clinic or other telehome monitoring program * women who are pregnant, breastfeeding or planning to become pregnant * patients who are institutionalized at a retirement home, nursing home or long-term care facility * patients who plan on travelling out of the country for more than 2 weeks at any point during the intervention phase of the study (first 3 months) * patients who are cognitively impaired or experiencing acute psychiatric illness that would alter their ability to participate
a phase 2 study to evaluate the efficacy and safety of qls1128 orally in symptomatic participants with mild to moderate covid-19

Conditions: COVID-19

Summary: a phase 2 study to evaluate the efficacy and safety of qls1128 orally in symptomatic participants with mild to moderate covid-19


Eligibility criteria:
inclusion criteria: 1. male or female subjects between ages of 18-80 years. 2. confirmed sars-cov-2 infection as determined by rt-pcr or antigen test in any specimen collected within 48 hours prior to randomization，first diagnosis of this infection within 72 hours prior to the randomization. 3. initial onset of the covid-19-related symptoms/signs within 48 hours prior to the randomization，and at least 1 of the covid-19-related symptoms/signs (cough,shortness of breath or difficulty breathing,fever,chills,body pain or muscle pain,diarrhea,nausea,vomiting，headache，sore throat，stuffy or runny nose)present on the day of randomization. exclusion criteria: 1. previous treatment with qls1128 sustained-release tablets or other 3cl protease inhibitors failed. 2. has received local approved anti-sars-cov-2 drugs within 7 days before screening or plan to receive them during the study period (e.g. paxlovid, azvudine, etc.) 3. has received monoclonal antibody against sars-cov-2 virus within 1 year prior to screening. 4. has received or expect to receive convalescent plasma therapy for covid-19 patients during the trial. 5. has received any cyp3a4/2c8 strong inducer within 28 days prior to screening or plan to receive any cyp3a4/2c8 strong inducer during the study period. 6. a known history of active liver disease , including acute/chronic hepatitis b, hepatitis c, cirrhosis, or acute liver failure. 7. allergic or have contraindications to test drugs or test drug excipients.
pulmonary hypertension in patients with myeloproliferative neoplasms

Conditions: Myeloproliferative Disorders; Pulmonary Hypertension

Summary: this is an observational prospective study aiming to clarify the prevalence of pulmonary hypertension in patients with myeloproliferative neoplasms and their prognosis. all patients attending our department with the above mentioned neoplasms will be offered inclusion in this study. all will have an echo performed and patients identified as being at risk of pulmonary hypertension will be offered complete investigation as specified by the european cardiology association. all patients will be followed up for a total of five years to identify prognosis.


Eligibility criteria:
inclusion criteria: * myeloproliferative neoplasms (pv, et, pmf according to who classification) exclusion criteria: * pregnancy * lack of informed consent * age \< 18 years * cognitive dysfunctions
phase ii study of lenalidomide/dexamethasone with or without elotuzumab for newly diagnosed mm patients in japan

Conditions: Multiple Myeloma

Summary: the purpose of this study is to determine the efficacy of lenalidomide/dexamethasone + elotuzumab in the subjects with newly diagnosed, previously untreated multiple myeloma (mm) in japan.


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * newly diagnosed with symptomatic multiple myeloma (mm) * have not received any prior systemic anti-myeloma therapy * have measurable disease * are not candidates for high-dose therapy plus stem-cell transplantation (sct) because of age (≥ 65 years) or coexisting conditions. refusal to undergo high dose therapy with sct is not sufficient for entry onto ca204-116 for a subject \< 65 years old. there must be a comorbidity that prevents sct for a subject \< 65 years old exclusion criteria: * non-secretory myeloma * smoldering mm, defined as asymptomatic mm with absence of lytic bone lesions * monoclonal gammopathy of undetermined significance (mgus) * active plasma cell leukemia * known human immunodeficiency virus (hiv) infection or active hepatitis a, b, or c
the spectralis-cirrus study

Conditions: Exudative Age Related Macular Degeneration

Summary: retinal thickness measurement is one of the most important examinations in the follow up of exudative age-related macular degeneration. prior studies have shown that there are a series of algorithm line failures in oct examinations. this study is conducted to compare the quality of the examinations of to different spectral domain oct machines concerning the positioning of algorithm lines. furthermore the reproducibility of the examinations id tested, both machines provide different techniques to guarantee that in repeated examinations the same location is examined.


Eligibility criteria:
inclusion criteria: * exudative age related macular degeneration exclusion criteria: * macular pathologies other than age related macular degeneration (diabetic maculopathy, macular pucker, macular hole, * visualization of the macula not possible (dens cataract, vitreous haemorrhage) * not consented patients

Keywords: retinal thickness threshold algorithm optical coherence tomography
analysis of genetic factors related to predisposition and prognosis of hematological malignancies in israel

Conditions: Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia

Summary: there are naturally occuring variations in the genetic makeup of all of us. some of these variations may contribute to a change in susceptibility toward different diseases or change the prognosis. we are studying these genetic variations in patients with leukemia. the genes we are studying are those which influence detoxification of drugs and toxins.

we have prepared dna on patients with leukemia (aml, cml and cll) and we are studying the influence of polymorphisms in drug metabolism and disposition genes on predisposition and prognosis of these types of leukemia. the genes we are studying include: mdr1, cyp3a4, nqo1, nat1/2, gst, hoct. we plan to study other genes that may be contributory. study includes comparing the frequency of polymorphisms in these genes with the frequency in the general population and the study of dna biding proteins which bind at the sites of these polymorphisms.

Eligibility criteria:
inclusion criteria: * diagnosis of acute myeloid leukemia or chronic lymphocytic leukemia exclusion criteria: * under 18 years of age

Keywords: drug metabolism and disposition enzymes
treatment of patients with blepharitis and facial rosacea

Conditions: Blepharitis; Meibomianitis; Dry Eye

Summary: to determine the safety and efficacy of sub-antimicrobial dose col-101 in the treatment of patients who have both blepharitis and facial rosacea


Eligibility criteria:
inclusion criteria: * blepharitis * facial rosacea exclusion criteria: * pregnant or nursing women * allergy to tetracyclines * recent eye surgery * past or current use of isotretinoin * patients who are achlorhydric * patients who have had gastric by-pass surgery
pharmacogenetics of liver toxicity in patients with multiple sclerosis treated with fingolimod

Conditions: Multiple Sclerosis

Summary: to investigate whether polymorphic differences can be identified between multiple sclerosis patients developing elevated liver enzymes (defined as alt, ast, ggt or bilirubinemia levels five above the upper normal limit on at least one) compared to those not developing elevated liver enzymes after exposure to fingolimod for multiple sclerosis.

purpose: to investigate whether polymorphic differences can be identified between multiple sclerosis (ms) patients treated by fingolimod who had liver enzymes elevation compared to those who do not. objective: to determine whether elevated liver enzyme tests (alt, ast, ggt or bilirubinemia above the upper limit of normal) in ms patients treated with fingolimod is associated with genetic polymorphisms. method of recruitment: patients will be identified through a clinic database and chart reviews. a phone call will be made to determine interest. upon a follow-up neurological consultation, consent into study will be sought. procedures: blood samples will be collected for genetic analyses, fingolimod and fingolimod-phosphate quantification and a questionnaire will be administered

Eligibility criteria:
inclusion criteria: * adults (\> 18 years) * have a definite multiple sclerosis with a relapsing-remitting course (mcdonald criteria) * treated with fingolimod * have given consent and signed an informed consent form exclusion criteria: * an elevated liver test result on baseline before starting fingolimod treatment * presence of a viral, hereditary or auto-immune liver pathology * time of fingolimod exposure lower than three months * woman currently pregnant or breastfeeding

Keywords: fingolimod hepatic adverse events polymorphism
glucose in dialysis water in diabetics with chronic renal failure

Conditions: Renal Failure, Chronic; Diabetic Nephropathies

Summary: the purposes are 1. to measure the effect of dialysis with glucose in dialysis water on blood pressure, pulse rate, plasma concentration of glucose, plasma concentrations og insulin, glucagon, growth hormone, renin, angiotensin ii, endothelin and body temperature, and 2. to analyse the relationship between the changes in blood pressure and changes in vasoactive hormones

the relationship between blood pressure during dialysis treatment and vasoactive hormones are studied. this includes measurements of plasma concentration of glucose, plasma concentrations og insulin, glucagon, growth hormone, renin, angiotensin ii, endothelin

Eligibility criteria:
inclusion criteria: 1. age \> 18 years, 2. both men and women, 3. dialysis treatment for at least three month due to diabetic nephropathy exclusion criteria: 1. heart failure, 2. lung insufficiency, 3. chronic liver disease, 4. malignant disease, 5. nephrotic syndrome, 6. lack of compliance, 7. unwillingness to participate

Keywords: hemodialysis, diabetes mellitus, chronic renal failure, dialysis ,
blastocyst culture using time-lapse in good prognosis ivf patients and elective single embryo transfer

Conditions: Infertility

Summary: choosing the best embryo for transfer has become the major challenge in in vitro fertilization (ivf). morphology alone is obviously not enough and time-lapse incubation has added embryo development kinetics as another selection criterion. this study was designed to select for the top blastocyst to be replaced, while increasing the pregnancy chance, with the local legislation regulating the number of embryos to be transferred and to establish a morphokinetic standard to be used in our clinical setting.


Eligibility criteria:
inclusion criteria: * patients in their first or second art treatment cycle * no recurrent spontaneous abortions * age\<35 years * bmi\<28 kg/m2 * ≥8 oocytes retrieved exclusion criteria: * severe endometriosis * polycystic ovary syndrome * hydrosalpynx * uterine pathology * severe male factor (presenting less than 5 million motile sperm cells in total in the ejaculate) * very severe morphological sperm defects (mainly globozoospermic or macrocephalic samples)

Keywords: time-lapse morphokinetics blastocyst transfer eset
pathophysiological mechanisms of dyspnea and activity-limitation in mild chronic obstructive pulmonary disease (copd)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: chronic obstructive pulmonary disease (copd) is a growing cause of death, disability and health care costs in canada. nevertheless, copd remains largely under-diagnosed and under-treated, particularly in its early stages. patients with mild copd have variable respiratory symptoms and often go unrecognized by their caregivers. recent studies indicate that even smokers with near normal breathing test results can have extensive small airway disease/dysfunction at rest, which becomes more pronounced during the stress of exercise thus leading to unpleasant breathing difficulty. this study seeks to better understand the nature and causes of breathing discomfort and activity limitation in a group of patients with mild copd. the investigators will compare detailed tests of small airway function and conduct an evaluation of several key physiological parameters during the stress of exercise in patients with mild copd and in healthy, age-matched, non-smoking control subjects. the investigators will also compare detailed physiological responses to exercise under conditions of chemical loading and mechanical unloading of the respiratory system in patients with mild copd. the proposed study will be the first to systematically test the hypothesis that pathophysiological abnormalities in ventilatory demand, pulmonary gas exchange, small airway function, dynamic ventilatory mechanics and respiratory muscle function contribute significantly to exertional dyspnea and activity-limitation in patients with mild copd. this study will be the first to determine if these abnormalities can be manipulated.


Eligibility criteria:
inclusion criteria: * post-bronchodilator forced expiratory volume in 1 sec (fev1) ≥ 80%predicted and a fev1/forced vital capacity (fvc) ratio \< 0.70; * clinically stable as defined by no changes in medication dosage or frequency of administration with no exacerbations or hospitalizations in the preceding 6 weeks; * a cigarette smoking history ≥ 20 pack-yrs; * body mass index between 18.5 and 30 kg/m2; * able to perform all study procedures and provide informed consent. exclusion criteria: * a diffusing capacity of the lung for carbon monoxide (dlco) \< 40 %predicted; * presence of active cardiopulmonary disease (or comorbidities) other than copd that could contribute to dyspnea and exercise limitation; * clinical diagnosis of sleep disordered breathing; * history or clinical evidence of asthma; * presence of important contraindications to clinical exercise testing, including inability to exercise because of neuromuscular or musculoskeletal disease(s); * use of daytime oxygen or exercise-induced arterial oxygen desaturation to \<80% on room air.

Keywords: mild copd dyspnea exercise respiratory mechanics copd